2.01
-0.08 (-3.60%)
| Previous Close | 2.09 |
| Open | 2.03 |
| Volume | 16,096 |
| Avg. Volume (3M) | 82,435 |
| Market Cap | 3,408,421 |
| Price / Sales | 3.18 |
| Price / Book | 0.600 |
| 52 Weeks Range |
| Operating Margin (TTM) | -2,151.43% |
| Diluted EPS (TTM) | -5.05 |
| Quarterly Revenue Growth (YOY) | -79.00% |
| Current Ratio (MRQ) | 1.70 |
| Operating Cash Flow (TTM) | -4.95 M |
| Levered Free Cash Flow (TTM) | -3.00 M |
| Return on Assets (TTM) | -100.63% |
| Return on Equity (TTM) | -218.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Tivic Health Systems, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -2.0 |
| Average | -0.75 |
|
Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body’s own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 12.81% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Dec 2025 | Announcement | Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package |
| 18 Nov 2025 | Announcement | Tivic Secures Barda Meeting for Entolimod(TM) for Acute Radiation Syndrome |
| 14 Nov 2025 | Announcement | Tivic Reports Third Quarter 2025 Financial Results |
| 13 Nov 2025 | Announcement | Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS) |
| 10 Nov 2025 | Announcement | Tivic Expands Intellectual Property Portfolio |
| 06 Nov 2025 | Announcement | Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast |
| 22 Oct 2025 | Announcement | Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23 |
| 22 Sep 2025 | Announcement | Tivic Health CEO Jennifer Ernst to Present at Emerging Growth’s September Virtual Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |